CAR-T cell therapy has reshaped the treatment of B-cell malignancies over the past decade. However, the conventional ex vivo CAR-T model—which requires cell collection, genetic modification, and reinfusion—remains complex, costly, and difficult to scale. In recent years, in ...Learn More

Biopharma PEG announced the expansion of its professional PEGylated protein development services, offering integrated, end-to-end solutions from recombinant protein expression to high-purity PEG conjugation and comprehensive analytical characterization. The platform is designed to ...Learn More

In the fast-evolving field of antibody–drug conjugates (ADCs), linker chemistry plays a decisive role in defining therapeutic performance. The ability to control the drug-to-antibody ratio (DAR), conjugation site, and overall molecular stability directly impacts both efficacy ...Learn More

Watertown, MA - June 29, 2025 - Biopharma PEG, a leading innovator in high-quality polyethylene glycol (PEG) derivatives, today announced it has successfully obtained Drug Master File (DMF) approval from the U.S. Food and Drug Administration (FDA) for its self-developed HZ-PEG-HZ ...Learn More

Antibody-drug conjugates (ADCs) combine potent small-molecule drugs with monoclonal antibodies for targeted cancer therapy. A major challenge is loading enough drug onto each antibody without compromising solubility or circulation time. Introducing polyethylene glycol (PEG) ...Learn More